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Sepsis is a leading cause of mortality and morbidity in neonates. Presenting clinical
symptoms are unspecific. Sensitivity and positive predictive value of biomarkers at onset
of symptoms are suboptimal. Clinical suspicion therefore frequently leads to empirical
antibiotic therapy in uninfected infants. The incidence of culture confirmed early-onset
sepsis is rather low, around 0.4–0.8/1000 term infants in high-income countries. Six to 16
times more infants receive therapy for culture-negative sepsis in the absence of a positive
blood culture. Thus, culture-negative sepsis contributes to high antibiotic consumption
in neonatal units. Antibiotics may be life-saving for the few infants who are truly infected.
However, overuse of broad-spectrum antibiotics increases colonization with antibiotic
resistant bacteria. Antibiotic therapy also induces perturbations of the non-resilient early
life microbiota with potentially long lasting negative impact on the individual‘s own health.
Currently there is no uniform consensus definition for neonatal sepsis. This leads to
variations in management. Two factors may reduce the number of culture-negative
sepsis cases. First, obtaining adequate blood cultures (0.5–1mL) at symptom onset is
mandatory. Unless there is a strong clinical or biochemical indication to prolong antibiotics
physician need to trust the culture results and to stop antibiotics for suspected sepsis
within 36–48 h. Secondly, an international robust and pragmatic neonatal sepsis definition
is urgently needed. Neonatal sepsis is a dynamic condition. Rigorous evaluation of clinical
symptoms (“organ dysfunction”) over 36–48 h in combination with appropriately selected
biomarkers (“dysregulated host response”) may be used to support or refute a sepsis
diagnosis.
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INTRODUCTION
Neonatal sepsis is a clinical manifestation of a systemic infection
during the first 28 days of life, usually classified as early-onset
(<48–72 h) and late-onset sepsis (>48–72 h), depending on the
age at onset of the sepsis episode (1). The inability to isolate
a microbial pathogen does not exclude sepsis (2, 3). The 2016
consensus definition of sepsis in adults (Sepsis-3) states that
sepsis is “a life-threatening condition caused by a dysregulated
host response to infection and organ dysfunction” (3). There
are also ongoing discussions regarding an adapted definition of
pediatric sepsis beyond the neonatal period, similar to the Sepsis-
3 definition (4, 5). However, there is unfortunately no uniform
consensus definition for neonatal sepsis (2, 6, 7). Many neonates
are therefore diagnosed with a “probable or possible” sepsis
or a “presumed symptomatic infection but no bacterial cause
identified” (8); conditions often referred to as “culture-negative
sepsis”(9).
Most publications on neonatal sepsis from high-income
countries only include culture-confirmed cases. The large
number of neonates treated with antibiotics for a culture-negative
sepsis are largely ignored in epidemiological studies. Thus, there
is a paucity of data on the latter condition. However, neonates
with culture-negative sepsis contribute to the high antibiotic
consumption seen in neonatal units (10, 11). Moreover, there
is a wide variation in antibiotic use between neonatal intensive
care units (NICUs) and countries, with no difference in infection-
attributable morbidity and mortality (10, 12). This indicates
probable overuse of antibiotics in some NICUs, which again
may have important adverse short- and long-term consequences
for the infant’s individual health (13–15). On the other hand,
delayed antibiotic therapy in truly infected neonates may result
in increased mortality and morbidity (16). Therefore, culture-
negative neonatal sepsis is at the crossroad between efficient
sepsis care and antimicrobial stewardship programs.
The main objective of this paper is to critically review the
controversial term culture-negative neonatal sepsis (9, 17), with a
focus on early-onset neonatal sepsis (EONS). We discuss how we
can combine efficient sepsis care with antimicrobial stewardship
during first days and weeks of life. Finally, we will discuss possible
strategies for defining EONS in the absence of a positive blood
culture.
EFFICIENT SEPSIS CARE—BASIC
ELEMENTS
Epidemiology
In most high-income countries, the incidence of culture-
confirmed EONS has decreased or remained relatively stable
around 0.4–0.8 cases per 1000 live-born term infants over the
last decade (10, 18–21). Although the incidence of EONS is
substantially higher in preterm infants, the majority of patients
with EONS are delivered at term (22). Robust epidemiological
data on culture-negative sepsis are limited. A number of
different studies published since 2012 report that infants
receiving systemic antibiotic therapy for culture-negative sepsis
outnumber infants receiving therapy for culture-confirmed
sepsis by a factor of six to 16 (Table 1). The reason for the high
number of culture-negative cases is not clear, and diagnostic
criteria used in the different publications vary substantially (10,
11, 23, 24, 26, 27). Low levels of bacteremia or only small volumes
of blood obtained from sick infants may be one explanation for
the high number of culture-negative sepsis cases. Also maternal
antibiotic treatment before or during delivery may theoretically
in some cases mask detection of bacteremia in the newborn.
However, one must also question whether over-diagnosis of
sepsis among non-infected infants is an alternative explanation.
Survivors of neonatal sepsis may suffer short- and long-term
consequences (28, 29). Delayed recognition and therapy of sepsis
increase the risk of morbidity and mortality and early antibiotic
treatment of suspected sepsis is a corner stone of every sepsis
care bundle (30). Therefore, clinicians have a low threshold to
suspect neonatal EONS and to start empirical antibiotic therapy.
Most probably due to a lack of a clear definition and a robust gold
standard of the diagnosis neonatal sepsis, started therapy is often
continued for 5–7 days, even in the absence of a positive blood
culture, to minimize the risk of “partial treatment” of a potential
true infection (11).
Risk Factors for EONS
Maternal group B streptococcal (GBS) colonization in the current
pregnancy, GBS bacteriuria, a previous infant with invasive GBS
disease, prolonged rupture of membranes (PROM; ≥18 h) and
maternal fever (temperature≥38◦C; often interpreted as a sign of
chorioamnionitis) are the risk factors most commonly associated
with EONS. These risk factors are additive; the presence of more
than one factor increases the likelihood of EONS (31, 32). EONS
prevention strategies using a risk factor based approach suggest
starting empiric antibiotics based on the presence of one or
more risk factors. These strategies decrease the incidence of GBS-
EONS (33, 34), but have poor predictive ability, leading to high
number of mothers and infants being treated with antibiotics. A
quantitative model assessing the indication for empiric therapy
including degree ofmaternal fever, duration of PROMand degree
of prematurity seem to perform better, and may reduce the
number of infants receiving antibiotics (35).
Reports and guidelines differ in their recommendations on
how to act on risk factor based strategies (36). The NICE-
guidelines do not specify whether the use of intrapartum
antibiotic prophylaxis alter the subsequent EONS risk assessment
and infant evaluation (8). In contrast, an EONS sepsis
calculator developed by Escobar and co-workers incorporates
that intrapartum antibiotic given >2–4 h prior to delivery
ameliorates the clinical recommendations regarding EONS risk,
and subsequent infant management (37). A recent international
survey regarding neonatal sepsis showed a broad variability
in management of neonates with only risk factors, whereas a
newborn with risk factors in combination with clinical signs were
uniformly started on antibiotic therapy (36).
Clinical Signs of EONS
EONS generally presents itself with respiratory distress, apnea,
lethargy or irritability, temperature instability, and feeding
difficulties. These symptoms are unspecific as many non-infected
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TABLE 1 | Reported cases of culture-confirmed vs. culture-negative neonatal sepsis in selected studies published after 2012.
Population and country Ratio culture-confirmed vs.
culture-negative sepsis cases
Definition culture-negative sepsis
Term infants admitted to neonatal units in
Norway over a 3 year period (n = 10 175) (10)
91: 1447 (1:16) • Physician assigned ICD-10 diagnosis P36.9
• Clinical symptoms
• Antibiotics ≥5 days
Term and preterm infants admitted to one
neonatal unit in Norway and one in Denmark
over a 3 year period (n = 2927) (23)
35: 203 (1:6) • Physician assigned ICD-10 diagnosis P36.9
• Clinical symptoms
• CRP > 10 mg/L
• Antibiotics ≥3 days
Term and preterm infants admitted within first
24 h of life to a single neonatal unit in Austria
(n = 851) (24)
31x: 209 (1:7) • Clinical symptoms
• Maternal risk factor or at least one abnormal laboratory marker (incl.
CRP > 8 mg/L)
Term and preterm infants evaluated for sepsis
in one neonatal unit in Canada (n = 1202) (25)
16: 107 (1:7) • Born to mothers receiving intrapartum antibiotics.
• Antibiotics started on the day of birth and continued for > 72 h
despite negative culture.
Infants born after 34 weeks gestation with
suspected EONS requiring antibiotics. A
multi-center study in Europe and Canada.
(n = 1710) (26)
27: 161 (1:6) Based on a risk classification scheme including:
• Maternal risk factors
• Clinical symptoms
• Laboratory findings (WBC < 5 x 109/mL and/or CRP > 10 mg/L)
Infants born after 34 weeks gestation at a
single institution in Switzerland over a 5-year
period (n = 11 503) (27)
4: 48 (1:12) • ≥2 clinical signs of sepsis within the first 7 days of life (temperature
instability, irritability, or lethargy, feeding difficulties, capillary refill >2 s,
apnea, tachycardia and/or tachypnea)
• CRP > 20 mg/L
• Antibiotics ≥7 days
x11 cases of positive tracheal cultures indicating invasive infections were reported in the original paper, but excluded here.
WBC, white blood cells; CRP, C-reactive protein; ICD-10, International Classification of Diseases, 10th revision.
neonates display similar symptoms. During the first days of
life, there is a dynamic adaption of different organ systems to
extra-uterine life. A single-point, clinical assessment to diagnose
EONS therefore seems impossible. Some guidelines suggest that a
respiratory rate> 50 or 60/min may be suggestive of an infection
(Table 2). However, in healthy infants the 95th percentile for
the respiratory rate is 65/min at 2 h of age (41). Moreover,
non-infected early term infants (37–38 weeks gestation) born
by cesarean section have high rates of transient tachypnea
(42). Feeding difficulties are also notoriously difficult to assess
during the first 1–2 days of life. A capillary refill time > 2 s
is included as a sign of EONS in some sepsis criteria (27, 43),
while observational studies indicate that the normal refill time
in neonates is at least 3 s (44, 45). These examples clearly show
the limitations with single-point assessments of clinical signs. In
preterm infants, symptoms from respiratory distress syndrome or
clinical instability may be impossible to differentiate from sepsis.
However, a number of preterm infants are delivered by cesarean
section, before rupture of membranes and with nomaternal signs
of infection. Among these there is a very low risk for EONS (46).
Recognizing a “low-risk situation” may provide the opportunity
to limit routine empiric antibiotics for preterm infants even when
there is some degree of respiratory distress. Nevertheless, there
is a broad consensus to start antibiotic therapy in newborns
with clinical signs suggestive of possible EONS (36)—the major
challenge is when to diagnose this as sepsis or to discard a sepsis
diagnosis and stop therapy!
Sensitivity and Positive Predictive Value of
Inflammatory Markers
In this paragraph we will focus on inflammatory markers that
are commonly used and commercially available today, namely
the complete blood cell (CBC) count, the C-reactive protein
(CRP), procalcitonin (PCT), and to some extent interleukins
(e.g., interleukin [IL]-6 and IL-8). It is not possible within the
scope of this article to review all biomarkers used for diagnostics,
and we refer to recent reviews on this topic (47). In the future,
rapid bedside point-of care tests using e.g., microarray chips to
quantify multiple cytokines and acute phase reactants and other
“multi-omic” approaches may become excellent and improved
diagnostic tools (47, 48).
The diagnostic value of the CBC-count and differential
with regard to neonatal sepsis has been extensively evaluated
(7, 49, 50). In general, CBC components are neither very
sensitive nor specific for EONS (49, 50). The white blood cell
(WBC) and the absolute neutrophil counts (ANC) are most
informative when very low (49, 50). There is a very wide range
between the lower and upper normal limits for WBC and
ANC. Increased band form neutrophils, represented by high
immature-to-total neutrophil ratio (IT-ratio), is often suggested
to indicate sepsis. However, large intra- and inter-laboratory
variation in interpretation limits its use (49, 51). Early onset
thrombocytopenia is commonly associated with feto-maternal
conditions and not very predictive for an infection (52). In the
setting of an EONS evaluation, a low platelet count has a low
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TABLE 2 | Selected examples of suggested neonatal sepsis definition from experts or societies.
Authors or society Criteria Comment
International pediatric sepsis
consensus conference: Definitions
for sepsis and organ dysfunction in
pediatrics−2005 (38)
Systemic inflammatory response syndrome (SIRS) criteria−1st week of
life
• Heart rate < 180/min or < 100/min
• Respiratory rate > 50/min
• WBC > 34 × 109/mL
• Core temperature of > 38.5◦C or < 36◦C
Sepsis; SIRS in the presence of suspected or proven infection
Evidence of infection vaguely
described
European Medicines Agency
definition from 2010 (39)
Criteria for inclusion in a neonatal sepsis clinical trial
Clinical sign (temperature instability, cardiovascular instability, skin symptoms,
respiratory instability, gastrointestinal symptoms, non-specific symptoms)
Laboratory signs: Low/high WBCs, I/T-ratio > 0.2, Platelet count < 100, CRP >
15 mg/L or PCT > 2 ng/mL, glucose intolerance and metabolic acidosis
Laboratory signs unspecific and
cut-offs with poor predictive ability
and not age adapted (PCT)
Wynn and Polin −2018 (2) Hypothetical neonatal sequential organ failure assessment (nSOFA)
score
Including the following 6 items with scores from 0 to 3:
Respiratory status, cardiovascular status, platelet counts, absolute neutrophil
count, renal function, and CNS function
Inclusion of WBC indices with poor
predictive values.
Hakonsson−2017 (40) Definition of a clinical, culture-negative GBS sepsis (in retrospect)
• Relevant symptoms and/or a CRP ≥ 25 mg/L
• GBS in the maternal vaginal/rectal swabs or superficial infant cultures
• The initiation of antibiotic therapy in the infant
Clinical signs not specified
Norwegian Neonatal Society (10) Definition of a culture-negative sepsis (in retrospect)
• Clinical symptoms
• CRP > 30 mg/L
• Other known clinical reasons for increased CRP excluded
• Received antibiotics ≥ 5 days
Clinical signs not specified.
Duration of antibiotics as a criteria
not useful prospectively
CRP, C-reactive protein; GBS, group B streptococci; CNS, central nervous system; WBC, white blood cells; PCT, procalcitonin, I/T ratio-immature to total neutrophil ratio.
sensitivity and a low positive predictive value (49, 53). Thus, CBC
components used alone are inaccurate to define neonatal sepsis in
the absence of a positive blood culture (7).
CRP is the most extensively studied acute-phase reactant
in neonates. It is widely available and its determination is
simple, fast, and cost-effective (54, 55). The mean CRP level
in healthy term infants undergoes a physiological rise from ∼1
mg/L at 12 h of age to ∼4 mg/L at 48 h of life (55). Preterm
infants have a less pronounced CRP response compared to
term infants (56). A CRP cut-off value at 10 mg/L is often
suggested as the upper normal limit (54). However, the 95th
percentile of CRP in healthy infants at 48 h of age is 12–14
mg/L (55, 57, 58). Moreover, non-infected infants may have
CRP values up to at least 40–50 mg/L, in particular after
vaginal delivery (58, 59). Thus, a substantial number of healthy
infants will have CRP values > 10 mg/L. CRP levels at the
time of initial EONS-evaluation have a low sensitivity (25),
because EONS usually originates during labor or at delivery
and it then takes 12–24 h for CRP to rise (54). The positive
predictive value of an elevated CRP value > 10 mg/L for
possible or proven EONS has also consistently been low. This
is mainly because there are multiple non-infectious conditions
associated with an inflammatory reaction in the perinatal
period, including a complicated labor and delivery, meconium
aspiration, intraventricular hemorrhage, and tissue injury (25, 54,
60).
Over the last decade, PCT has emerged as a promising and
increasingly used sepsis biomarker in neonates. PCT, like CRP,
does not cross the placenta; hence is not affected by maternal
fever in labor (61). PCT levels start to rise 2 h after start of a septic
insult and peak by 12 h (62). The earlier rise after onset of the
infectious stimulus makes PCT an attractive alternative to CRP
(63). However, there has been few high-quality studies reporting
data on the clinical usefulness of PCT at disease onset in “ruling
in” EONS (63). Moreover, the interpretation of PCT values is
challenging due to a strong physiological rise and fall during the
first 72 h of life. Other perinatal factors, such as chorioamnionitis,
hypoxemia, perinatal asphyxia, and maternal preeclampsia, can
also cause PCT to increase (64). Dynamic reference values of
PCT in neonates with and without EONS have been published
(57, 65, 66).
Interleukins, predominantly IL-6 and IL-8, are used routinely
in some countries and are considered as sensitive “early warning
biomarkers” (47, 67, 68). The advantage of using interleukins is
the early spike after an infectious insult that may add in early
diagnosis. However, due to their short half-life one may not
catch the peak level and this may limit sensitivity. Thus, when
used they should always be combined with a “later marker” e.g.,
CRP (67).
In summary, the positive predictive values of the above-
mentioned inflammatory markers are relatively low. The reason
for this is mainly due to perinatal inflammatory reactions
triggered by factors during delivery or in the early postnatal
period. Still, many clinicians use abnormal inflammatorymarkers
at disease onset as one reason to prolong antibiotic therapy in
infants with a negative blood culture (36).
Frontiers in Pediatrics | www.frontiersin.org 4 October 2018 | Volume 6 | Article 285
Klingenberg et al. Culture-Negative Neonatal Sepsis
ANTIMICROBIAL STEWARDSHIP IN THE
NEONATAL UNIT
Prolonged Antibiotic Therapy in the
Neonatal Period and Associated Risks
The duration of antimicrobial therapy in infants with negative
blood cultures is controversial, and there is little evidence
to inform practice (8, 31). In the SCOUT-study researchers
assessed antibiotic consumption for different conditions among
2500 term and preterm infants (11). Culture-proven infection
and necrotizing enterocolitis (NEC) accounted for only 6.9%
of antibiotic use. In contrast, prolonged (≥ 5 days) antibiotic
therapy for pneumonia or culture-negative sepsis accounted for
26% of total antibiotic use and therapy was continued for median
(range) seven (5–14) days for these conditions. The UK NICE-
guidelines states that the usual duration of antibiotic treatment
for babies with a positive blood culture, and for those with
a negative blood culture but in whom there has been strong
suspicion of sepsis, should be 7 days (8). In observational studies,
infants with culture-negative sepsis are commonly treated for 5–
7 days and mortality is very low (10, 11, 23). However, due to
variable sepsis definitions it is not possible to assess “safety” vs.
a clear possibility of harm due to overtreatment (69). A recent
study from India compared the efficacy of 7 vs. 10 days duration
of intravenous antibiotics for culture-proven septic neonates and
found no difference (70).
There is growing evidence that prolonged antibiotic therapy
in preterm infants without proven infection increases the risk
of mortality, bronchopulmonary dysplasia, NEC, retinopathy,
and periventricular white matter damage (13, 71). The question
if antibiotic therapy is a perpetrator or an innocent bystander
is still not completely clear, but we must seriously consider
that the “administration of antibiotics itself may contribute to
mortality and morbidity among preterm infants” (72). It has also
been known for decades that overuse of antibiotics paves the
way for development of multi-resistant bacteria and there is an
urgent call for rational use of antibiotics (73). Unfortunately,
the cost of antibiotic resistance for the community compared to
the potential risk of delayed or insufficient treated infection is a
weak argument for the clinician at the bedside. With the growing
knowledge of antibiotic use and the cost on the individual‘s own
health via the collateral damage on their microbiota, this may
change (74). Recent data indicate that the perturbations of the
non-resilient microbiota in early life may influence both the
immune system and stem cell populations with potential negative
impact on future health (75–77). Therefore, pediatricians and
neonatologists need to measure risk and benefits of every dose of
antibiotics for culture-negative situations. The hospitals and lead
clinicians in neonatal units have an independent responsibility
to educate and keep staff updated about current knowledge
of the harmful effects of unnecessary antibiotic use in the
neonatal period (78). Recent publications reporting results from
antimicrobial stewardship programs in NICUs highlight both
the potential for improving antibiotic prescription practice, but
also challenges when trying to reduce broad-spectrum antibiotic
therapy in vulnerable very preterm infants (79, 80).
Appropriate Blood Culture Diagnostics
A positive microbial culture from a normally sterile site (blood)
is frequently used as the gold standard to define neonatal sepsis
(2). In the UK, around 50% of all blood cultures obtained in the
neonatal period were taken on the day of birth, but only 0.8%
of these were positive (81). Thus, the majority of blood cultures
are negative in neonates who are evaluated with risk factors or
clinical signs of EONS. What is the sensitivity of blood cultures
in neonates? Schelonka analyzed, in a laboratory-based study,
a range of blood volumes containing known concentrations
of common neonatal pathogens injected into pediatric blood
culture bottles. If organisms were present at very low densities
[< 4 colony forming units (cfu)/mL] a blood culture volume
of 1.0mL was needed to detect bacteremia. Otherwise, blood
culture volumes down to 0.5mL were sufficient to detect most
bacteremia’s. In a similar in-vitro study, placental blood seeded
with more than 10 cfu/mL of E. coli or GBS required only
0.25mL blood to be consistently detected (82). Thus, blood
cultures with a volume of 1.0mL have excellent sensitivity even
when the infant has low very levels of bacteremia, and blood
culture volumes down to as little as 0.5mL may be sufficient
to detect moderate and high grade bacteremia (83). Some
authorities recommend obtaining at least two cultures (aerobic
and anaerobic) before commencing antibiotics, but there are
no neonatal data to support this, and usual practice is to take
only one aerobic blood culture bottle before starting antibiotic
treatment (84).
Quantitative blood culture methodology (cfu/mL) is not
routinely used. However, blood culture time to positivity (TTP)
correlates to level of bacterial density as TTP is inversely
proportional to the inoculated bacterial concentration. Using
modern continuous monitoring blood culture system, median
TTP of blood cultures in neonatal sepsis is 9–18 h for true
pathogenic bacteria (85–89). For GBS and E. coli around 96–
100% are positive by 36 h (85, 86, 89), whereas coagulase negative
staphylococci may take up to 48 h to be detected. Maternal
intrapartum antibiotic therapy does not seem to delay TTP
(85, 90). Thus, considering TTP aids in clinical interpretation
of blood culture results and is the reason why central guidelines
suggest stopping antibiotics if culture results are negative at
36–48 h (8, 31). Ensuring a sufficient blood culture volume
(minimum 0.5mL) and adequate routines for 24/7 immediate
entry of blood culture bottles into the blood culture system are
essential elements in this diagnostic algorithm (84, 87, 91).
Modern molecular methods may potentially represent more
rapid, sensitive, and specific ways of identifying bacteria. These
methods include conventional and real-time polymerase chain
reaction (PCR) assays targeted at universal and specific gene sites.
A systematic review from 2017 concluded that molecular assays
have the advantage of producing rapid results and may perform
well as “add-on” tests, but cannot replace microbial cultures in
the diagnosis of neonatal sepsis (92, 93). This may change in
the future. A recent publication reports promising results using
multiplex real-time PCR in late-onset neonatal sepsis with results
potentially available within 4 h of blood sampling and good
concordance with blood culture results (94).
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Negative Predictive Value of Inflammatory
Markers
In contrast to the low positive predictive value, the negative
predictive value of some inflammatory markers like CRP and
PCT, and in combination with ILs, are good (26, 54, 67).
Available evidence indicates that PCT may have the highest
negative predictive value for severe, invasive bacterial infections
in neonates (95, 96). Some high-quality intervention studies
also show superiority of biomarker-guided duration of antibiotic
therapy in neonatal (early- or late-onset) sepsis compared to a
standard protocol (26, 67, 68, 97). The NICE-guideline states that
if continuing antibiotics for longer than 36 h despite negative
blood cultures, one should review the baby at least once every
24 h. Each day one should consider whether it is appropriate to
stop antibiotic treatment, taking account of the level of initial
clinical suspicion of infection, the baby’s clinical progress and
current condition, and whether there are “reassuring” levels and
trends of CRP (8). One potential weakness with this high-quality
guideline is the lack of discussion around which CRP values
that can be interpreted as “reassuring.” After implementing the
NICE guidelines recommending measuring CRP 18–24 h after
commencing antibiotics, one report in fact showed that this
led to more investigations and longer duration of antibiotic
treatment (98).
A recent large randomized trial showed that PCT-guided
decision-making was superior to standard care in reducing
antibiotic therapy in neonates with suspected EONS. Clinicians
may still “struggle” to become familiar with postnatal age specific
PCT cut-off values over the first few 72 h of life which may
confound the interpretation of a negative and a positive PCT
value for the diagnosis of EONS. Therefore, a web-based guide
for PCT-guided decision-making will hopefully be published in
2018-2019 (personal communication). A survey performed in
2011-2012 in Europe, North-America and Australia showed that
PCT at that time was not as widely used as CRP to diagnose
EONS (36). However, like for CRP, PCT seems to be an excellent
additional tool to rule out EONS as long as age specific values are
taken into account.
FUTURE DEFINITION OF NEONATAL
SEPSIS
The International Classification of Diseases, 10th Revision (ICD-
10), defines different subtypes of bacterial sepsis in the newborn
(P36). When specific pathogens are identified in the blood
culture, the codes P36.0-8 are applied. For all other cases,
e.g., when the clinician “believes” the newborn has sepsis the
code P36.9 “unspecified bacterial sepsis” is applied. Regional
differences in the use of P36.9 clearly exemplifies the need for a
uniform sepsis definition (10). Both the US and the UK EONS-
guidelines present the typical clinical symptoms thatmay indicate
EONS, but do not specify clinical criteria defining sepsis in the
absence of a positive blood culture (8, 31). Examples of some
suggested neonatal sepsis criteria are presented in Table 2.
How can we define sepsis in neonates with a negative blood
culture? Current adult sepsis definition is a “dysregulated host
response to infection and organ dysfunction.” An adoption
of this definition for neonatal sepsis may be possible, but
the terms “dysregulated host response,” “infection,” and “organ
dysfunction” need to be defined for the neonatal population.
Interestingly, there are no risk factors included in the new adult
Sepsis-3 definition, although risk factors also exist for sepsis in
the adult population. Risk factors for EONS are well anchored
in the sepsis framework for pediatricians and neonatologists.
Clinical symptoms of sepsis may overlap with non-inflammatory
conditions and we suggest that parameters reflecting a host
inflammatory response (“dysregulated host response”) need to be
included in order to establish a sepsis diagnosis in the absence
of growth in a blood culture. Moreover, the biochemical picture
of neonatal sepsis changes over the first days after antibiotics
has been commenced for a suspected sepsis episode, and the
kinetics of inflammatory biomarkers could also be included in
a future sepsis definition. Finally, there is an urgent need for an
international definition of organ dysfunction in neonates, which
for the first days of life require a dynamic evaluation. Wynn
and Polin recently called for a consensus definition of neonatal
sepsis (5). As a group of European authors on neonatal sepsis we
strongly agree with this call for action.
FUTURE STRATEGIES FOR EFFICIENT
MANAGEMENT OF CULTURE-NEGATIVE
SEPSIS
Two important factors may substantially reduce the number of
cases coined as culture-negative sepsis.
First, available evidence indicate that blood cultures in
neonates are highly sensitive, at least down to volumes of 0.5–
1.0mL. In neonatal units with available equipment and resources
for obtaining blood cultures this diagnostic procedure must
always be performed prior to commencing antibiotic therapy,
with adequate aseptic technique and drawing a sufficient volume,
preferably 1mL and minimum 0.5mL (9). We suggest to clearly
record in the patient chart the blood culture volume taken.
Automated 24-h electronic systems for reporting negative or
positive (i.e., growth detected) blood culture results at 36–
48 h incubation should be implemented in each hospital to
support clinical decision-making of stopping antibiotics. Unless
there is a strong clinical or biochemical indication to prolong
antibiotics physician need to trust the culture results when
an adequate volume is obtained and to stop antibiotics for
suspected sepsis within 36–48 h. Our recommendations are
in line with a recently published perspective article entitled
“ending the culture of culture-negative sepsis in the neonatal
ICU” where the authors urgently ask clinicians to trust negative
cultures (9).
Second, a robust and pragmatic neonatal sepsis definition
may reduce subjective variations in antibiotic use and support
clinicians providing “appropriate” antibiotic therapy to those
infants who need antibiotics. EONS is a dynamic and complex
condition. A static definition of clinical symptoms reflecting
organ dysfunction at a single point (disease onset) is most likely
too unspecific to define EONS and guide antibiotic therapy.
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A combination of risk factors, symptoms at disease onset
combined with development of symptoms upon evaluation after
36–48 h is an alternative approach. This would concomitantly
be in line with clinical guidelines strongly suggesting reviewing
the infant and deciding whether one should stop treatment
of suspected EONS after 36–48 h. Escobar and co-workers
developed an electronic sepsis calculator applicable for newborns
≥34 weeks’ gestation including both quantitative maternal risk
factors and clinical symptoms after birth. Implementation of
this calculator in routine clinical care has been associated with
a substantial and concomitantly and probably safe reduction
in the number of infants commenced on antibiotics for
suspected EONS in several countries (35, 99, 100). We believe
a similar strategy for diagnosing EONS; including development
of clinical symptoms over 36–48 h combined with a biomarker-
guided approach may further reduce the unnecessary prolonged
duration of antibiotic treatment. CRP and PCT, optionally
combined with interleukin 6 or 8, are currently the most
attractive biomarkers for this purpose.
In conclusion, there is a need to align the road toward efficient
sepsis care with the road toward antimicrobial stewardship in
the neonatal unit. Early antibiotic therapy for truly infected
newborns is crucial for an optimal outcome. On the other
hand, prolonged antibiotic therapy for non-infected newborns
is harmful for their microbiota, for their future health and for
the community.
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